Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Impact of allogeneic transplant vs hypomethylating agents in high-risk myelodysplastic syndromes: A prisma-guided systematic review

View Full Paper
Ask AI
Bookmark
Share

Authors

KPKeyur P. PatelJGJanamejey Gaur

Discussion

Loading...

Member takes

Overview

Systematic review shows hypomethylating agents offer limited control, indicating allogeneic transplant improves survival.

Key Points

  • To compare the effects of allogeneic transplant and hypomethylating agents in high-risk myelodysplastic syndromes.
  • Conducted a systematic review following PRISMA-2020 guidance
  • Included studies comparing allo-HSCT with non-transplant therapy
  • Assessed risk-of-bias using RoB-2 or Newcastle–Ottawa
  • Allogeneic transplant shown to improve overall survival compared to hypomethylating agents.
  • High rates of leukaemia-free survival achieved within transplantation group by reducing relapse rates.
  • TP53 mutation is a key factor that influences outcomes and treatment considerations.

Cite This Study

Patel et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfd7https://doi.org/10.1182/blood-2025-7369
View Full Paper
Ask AI
Bookmark
Share